Ratings by Leerink (Faisal Khurshid)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/9/2026 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2025 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2025 | AbCellera Biologics | ABCL | Downgrade | Market Perform (Outperform) |
4.53 (5.31) |
17.22% | Details | |
| 10/10/2025 | Nurix | NRIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/15/2025 | aTyr Pharma | ATYR | Downgrade | Market Perform (Outperform) |
6.03 (0.47) |
-92.21% | Details | |
| 9/12/2025 | Protagonist Therapeutics | PTGX | New Coverage | Outperform (N/A) |
59.68 (136.11) |
128.07% | Details | |
| 8/21/2025 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2025 | Shattuck Labs | STTK | Maintain | Outperform (N/A) |
|
Details | ||
| 7/9/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2025 | AbCellera Biologics | ABCL | New Coverage | Outperform (N/A) |
3.80 (4.53) |
19.21% | Details | |
| 7/7/2025 | Rhythm Pharmaceuticals | RYTM | New Coverage | Outperform (N/A) |
65.77 (102.10) |
55.24% | Details | |
| 6/26/2025 | aTyr Pharma | ATYR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/25/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/4/2025 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2025 | Nurix | NRIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/8/2025 | Spyre | SYRE | New Coverage | Outperform (N/A) |
12.39 (102.13) |
724.29% | Details | |
| 3/17/2025 | Nurix | NRIX | New Coverage | Market Perform (N/A) |
13.59 (23.38) |
72.04% | Details | |
| 3/17/2025 | Shattuck Labs | STTK | New Coverage | Outperform (N/A) |
1.19 (7.53) |
532.77% | Details | |
| 2/18/2025 | aTyr Pharma | ATYR | New Coverage | Outperform (N/A) |
3.41 (6.03) |
76.83% | Details | |
| 12/16/2024 | PureTech Health | PRTC | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2024 | Lantheus Holdings | LNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2024 | PureTech Health | PRTC | New Coverage | Outperform (N/A) |
20.36 (17.42) |
-14.44% | Details | |
| 9/9/2024 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
45.40 (110.57) |
143.55% | Details | |
| 3/19/2024 | Fusion Pharmaceuticals | FUSN | Downgrade | Market Perform (Outperform) |
10.64 (21.55) |
102.54% | Details | |
| 5/23/2023 | Rain Therapeutics | RAIN | Downgrade | Market Perform (Outperform) |
9.93 (1.46) |
-85.3% | Details | |
| 3/21/2023 | Rain Therapeutics | RAIN | New Coverage | Outperform (N/A) |
7.77 (1.46) |
-81.21% | Details | |
| 11/30/2022 | Lantheus Holdings | LNTH | New Coverage | Outperform (N/A) |
60.65 (104.82) |
72.83% | Details |
